Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 12/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 11/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.41 |
| ▸ | CCNK | O75909 | 2/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.41 |
| ▸ | CDK13 | Q14004 | 2/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23508404 | 0.92 | CSNK1D (0.44) | CSNK1ECSNK1DHPGD | |
| SCHEMBL23497861 | 0.92 | CSNK1D (0.44) | CSNK1ECSNK1DHPGD | |
| SCHEMBL30013457 | 0.92 | CSNK1D (0.44) | CSNK1ECSNK1DHPGD | |
| SCHEMBL23497452 | 0.91 | CSNK1D (0.44) | CSNK1ECSNK1DHPGD | |
| SCHEMBL30013448 | 0.91 | CSNK1D (0.44) | CSNK1ECSNK1DHPGD | |
| SCHEMBL23508330 | 0.90 | CSNK1D (0.53) | CSNK1ECSNK1DGSK3B | |
| SCHEMBL30012915 | 0.89 | CSNK1E (0.48) | CSNK1ECSNK1DNR2F2CDK12CCNK | |
| SCHEMBL23497781 | 0.89 | CSNK1E (0.48) | CSNK1ECSNK1DNR2F2CDK12CCNK | |
| SCHEMBL23508633 | 0.89 | CSNK1E (0.55) | CSNK1ECSNK1DHPGDTP53PIK3CD | |
| SCHEMBL23497423 | 0.89 | CSNK1D (0.53) | CSNK1ECSNK1DHPGDTP53PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4073072-A1 | PYRAZOLOTRIAZINES | Bayer Aktiengesellschaft (DE) | 2022-10-19 | — | — | EP | claimed |
| US-20230192700-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230192700-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
| EP-4114528-A1 | IMIDAZOTRIAZINES ACTING ON CANCER VIA INHIBITION OF CDK12 | Bayer Aktiengesellschaft (DE) | 2023-01-11 | — | — | EP | disclosed |
| EP-4114837-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | Bayer Aktiengesellschaft (DE) | 2023-01-11 | — | — | EP | disclosed |
| EP-4073072-A1 | PYRAZOLOTRIAZINES | Bayer Aktiengesellschaft (DE) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021176049-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | BAYER AKTIENGESELLSCHAFT (DE) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021176045-A1 | IMIDAZOTRIAZINES ACTING ON CANCER VIA INHIBITION OF CDK12 | BAYER AKTIENGESELLSCHAFT (DE) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021116178-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BRCA1, TPX2, CCND2 | CSNK1E 1596/4885CSNK1D 963/4885HPGD 127/4885 |
| US-20230192700-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | CDK12, CDK1, CDK15 | CSNK1E 338/4885CSNK1D 300/4885HPGD 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.